SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Nutex Health, Inc. (NUTX) (CIK 0001479681) (NUTX) — Apr 5, 2023

Nutex Health, Inc. (NUTX) (CIK 0001479681)
Date: April 5, 2023 · CIK: 0001479681 · Accession: 0000000000-23-003412

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-270886

Date
April 5, 2023
Author
Thomas T. Vo
Form
UPLOAD
Company
Nutex Health, Inc. (NUTX) (CIK 0001479681)

Letter

United States securities and exchange commission logo April 5, 2023 Thomas T. Vo Chief Executive Officer Nutex Health Inc. 6030 S. Rice Ave., Suite C Houston, TX 77081 Re:Nutex Health, Inc. Registration Statement on Form S-3 Filed March 28, 2023 File No. 333-270886 Dear Thomas T. Vo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Kate Beukenkamp at 202-551-3861 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Gislar Donnenberg

Show Raw Text
United States securities and exchange commission logo
April 5, 2023
Thomas T. Vo
Chief Executive Officer
Nutex Health Inc.
6030 S. Rice Ave., Suite C
Houston, TX 77081
Re:Nutex Health, Inc.
Registration Statement on Form S-3
Filed March 28, 2023
File No. 333-270886
Dear Thomas T. Vo:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Kate Beukenkamp at 202-551-3861 with any questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:       Gislar Donnenberg